HOME >> BIOLOGY >> NEWS
Early promise for treatment of Ebola

Preliminary findings of an animal study in this week's issue of THE LANCET suggest that scientists have taken an important step towards a possible treatment strategy for the deadly Ebola virus.

Haemorragic fever from the Ebola virus is fatal in up to 80%of cases in humans. The virus is thought to cause excessive blood coagulation and thrombosis leading to organ dysfunction. Inhibition of the blood coagulation pathway could therefore be a potential therapeutic approach for ebola treatment.

Thomas W Geisbert from the US Army Medical Research Institute of Infectious Diseases and colleagues injected 12 rhesus macaques with the ebola virus to induce the deadly ebola haemorragic fever. Nine of the macaques received an inhibitor of the blood coagulation pathway (called recombinant nematode anticoagulant protein c2, rNAPc2), while three macaques received the ebola virus only (the control group).

Treatment with rNAPc2 prolonged survival time and resulted in a 33% survival rate; this contrasted with macaques in the control group, of whom all except one died (since the study was completed the remaining control animal has also died). The surviving macaques in the treatment group were in good health nine months after the study. Survival was longer (12 days) for treated macaques who died compared with untreated macaques in the control group (8 days).

Thomas W Geisbert comments: "Our results have great clinical implications, since our treatment approach of Ebola haemorrhagic fever targets the disease process rather than replication of the infectious agent. Moreover, our findings raise the possibility that rNAPc2 could be useful in the treatment of other viral haemorrhagic fevers. Importantly, rNAPc2 has a suitable phamacokinetic and safety profile in human beings. The clinical efficacy of this treatment modality now needs to be proven."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
11-Dec-2003


Page: 1

Related biology news :

1. Berkeley Lab soil scientist Margaret Torn receives Presidential Early Career Award
2. Early detection hope for eye disease
3. Early clinical treatment can halt progression of Alzheimers disease, UCI researchers find
4. Early dexamethasone exposure has long-term neurodevelopment, neuroendocrine effects
5. Early predictor of breast cancer aggressiveness
6. Early treatment confirmed as key to stroke recovery
7. Early identification of kidney disease cost-effective only when directed at high-risk patients
8. Early treatment can prevent severe vision loss in premature infants
9. Early hominids may have behaved more human than we had thought
10. Early infection and rejection detection
11. Early-life environments shape development of stress behaviors and learning abilities in mice

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 24, 2020 , ... Elgia Therapeutics , ... fibrotic diseases, today announced that Dr. Stacie Canan has joined the company as ... previously served as Executive Director of Global Health at Bristol Myers Squibb (formerly ...
(Date:8/26/2020)... (PRWEB) , ... August 25, 2020 , ... Modality ... made Inc. magazine’s 2020 annual Inc. 5000 list. The list is the most prestigious ... in 2019 as well, and for this year’s list, reported three-year revenue growth of ...
(Date:8/21/2020)... , ... August 19, 2020 , ... ... LLC and SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than twenty ... recently published book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands company ... Known as MediVet Biologics since its formation in 2016, the company is relaunching ... Health will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... Texas (PRWEB) , ... July 29, 2020 , ... ... solutions today announced the launch of its new tagline, “BUILDING FOR LIFE.” The ... biopharmaceutical industry and around the globe, requiring fast track capacity to provide patients ...
(Date:7/31/2020)... SHREWSBURY, Mass. (PRWEB) , ... July 29, 2020 ... ... clad wire that can combine up to three different materials for use with ... can combine up to three materials to meet specific design requirements, performance, and ...
(Date:7/31/2020)... , ... July 29, 2020 , ... eSource has long ... This webinar will cover the history of eSource, the reasons it did not take ... to wearables, to site source, the industry is moving towards capturing data electronically for ...
Breaking Biology Technology:
Cached News: